Cardiovascular risk factors in patients at high risk of atherothrombosis: What can be learned from registries?

Shinya Goto

doi:10.1160/TH08-06-0388

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2008; 100(04): 611-613
DOI: 10.1160/TH08-06-0388

Clinical Focus

Schattauer GmbH

Cardiovascular risk factors in patients at high risk of atherothrombosis: What can be learned from registries?

Shinya Goto

¹Department of Medicine (Cardiology) and the Metabolic Disease Center of Tokai University Graduate School of Medicine, and the Department of Metabolic Systems Medicine, Institute of Medical Science, Tokai University, Kanagawa, Japan

› Institutsangaben

Abstract

als PDF herunterladen

PDF (616 kb)

Referenzen

References
1 Wilson PW. et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
2 Arcelus JI. et al. Clinical presentation and time-course of postoperative venous thromboembolism: Results from the RIETE Registry. Thromb Haemost 2008; 99: 546-551.
3 Ruiz-Gimenez N. et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100: 26-31.
4 Blanco-Molina A. et al. Venous thromboembolism during pregnancy or postpartum: findings from the RIETE Registry. Thromb Haemost 2007; 97: 186-190.
5 Falga C. et al. Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry. Thromb Haemost 2007; 98: 771-776.
6 Cohen AT. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-764.
7 Ivaskevicius V. et al. International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost 2007; 97: 914-921.
8 Fox KA. et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). Br Med J 2006; 333: 1091.
9 Bradshaw PJ. et al. Validity of the GRACE (Global Registry of Acute Coronary Events) acute coronary syndrome prediction model for six month post-discharge death in an independent data set. Heart 2006; 92: 905-909.
10 Parikh NI. et al. A risk score for predicting near-term incidence of hypertension: the Framingham Heart Study. Ann Intern Med 2008; 148: 102-110.
11 Touboul PJ. et al. Correlation between the Framingham risk score and intima media thickness: the Paroi Arterielle et Risque Cardio-vasculaire (PARC) study. Atherosclerosis 2007; 192: 363-369.
12 Wang TJ. et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. J Am Med Assoc 2003; 290: 1049-1056.
13 Gordon T. et al. Death and coronary attacks in men after giving up cigarette smoking. A report from the Framingham study. Lancet 1974; 02: 1345-1348.
14 Freund KM. et al. The health risks of smoking. The Framingham Study: 34 years of follow-up. Ann Epidemiol 1993; 03: 417-424.
15 Kannel WB. et al. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 1979; 90: 85-91.
16 Wilson PW. et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162: 1867-1872.
17 Rosito GA. et al. Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost 2004; 91: 683-689.
18 Teo KK. et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006; 368: 647-658.
19 Rosengren A. et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 953-962.
20 Verschuren WM. et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. J Am Med Assoc 1995; 274: 131-136.
21 Tunstall-Pedoe H. et al. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999; 353: 1547-1557.
22 Kubo M. et al. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 2003; 34: 2349-2354.
23 Katsuki S. et al. Epidemiological Studies on Cer-ebrovascular Diseases in Hisayama, Kyushu Island, Japan. I. With Particular Reference to Cardiovascular Status. Jpn Heart J 1964; 127: 12-36.
24 Kiyohara Y. et al. Ten-year prognosis of stroke and risk factors for death in a Japanese community: the Hisayama study. Stroke 2003; 34: 2343-2347.
25 Ueda K. et al. Intracerebral hemorrhage in a Japanese community, Hisayama: incidence, changing pattern during long-term follow-up, and related factors. Stroke 1988; 19: 48-52.
26 Fujishima M. et al. Diabetes and cardiovascular disease in a prospective population survey in Japan: The Hisayama Study. Diabetes 1996; 45 (Suppl. 03) S14-6.
27 Ohmori S. et al. Hyperinsulinaemia and blood pressure in a general Japanese population: the Hisayama Study. J Hypertens 1994; 12: 1191-1197.
28 Saito T. et al. Relationship between obesity, glucose tolerance, and periodontal disease in Japanese women: the Hisayama study. J Periodontal Res 2005; 40: 346-353.
29 Ueda K. et al. Prevalence and long-term prognosis of mild hypertensives and hypertensives in a Japanese community, Hisayama. J Hypertens 1988; 06: 981-989.
30 Fujii I. et al. Natural history of borderline hypertension in the Hisayama community, Japan--I. The relative prognostic importance of transient variability in blood pressure. J Chronic Dis 1984; 37: 895-902.
31 Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Committee of the Physicians’ Health Study Research Group. N Engl J Med. 1989 321. 129-135.
32 Patrono C. et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-2383.
33 Worth RM. et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: mortality. Am J Epidemiol 1975; 102: 481-490.
34 Ro A. et al. The factor V Leiden mutation and the prothrombin G20210A mutation was not found in Japanese patients with pulmonary thromboembolism. Thromb Haemost 1999; 82: 1769.
35 Ozawa T. et al. Absence of factor V Leiden in the Japanese. Thromb Res 1996; 81: 595-596.
36 Bhatt DL. et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. J Am Med Assoc 2006; 295: 180-189.
37 Yamazaki T. et al. Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan. Circ J 2007; 71: 995-1003.
38 Ohman EM. et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006 151. 786 e1–10.
39 Steg PG. et al. One-year cardiovascular event rates in outpatients with atherothrombosis. J Am Med Assoc 2007; 297: 1197-1206.